Informed choice of composite end points in cardiovascular trials

Circulation: Cardiovascular Quality and Outcomes

Volumn 7, Issue 1, 2014, Pages 170-178

  Gómez, Guadalupe ^a   Gómez Mateu, Moisés ^a   Dafni, Urania ^b  

^a UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Asymptotic relative efficiency; Cardiovascular drugs; Clinical trials; Randomized

Indexed keywords

FONDAPARINUX; SUCCINOBUCOL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COMPOSITE END POINT; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; FOLLOW UP; HAZARD RATIO; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MEASUREMENT; MEDICAL RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW (TOPIC); VALVULAR HEART DISEASE;

ASYMPTOTIC RELATIVE EFFICIENCY; CARDIOVASCULAR DRUGS; CLINICAL TRIALS, RANDOMIZED; COMPOSITE END POINT; LOGRANK TEST;

CARDIOVASCULAR DISEASES; CHOICE BEHAVIOR; DATA COLLECTION; ENDPOINT DETERMINATION; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84898746008     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000149     Document Type: Article

References (25)

1. Meinert CL. Clinical Trials Dictionary: Terminology and Usage Recommendations. Baltimore, MD: The Johns Hopkins Center for Clinical Trials. 1996. ISBN 0-9646424-0-9.
2. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: composite end points. J Card Fail. 2005;11:567-575.
3. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in Randomized Trials. Greater precision but with greater uncertainty? JAMA. 2003;289:2554-2559.
4. Gómez G, Lagakos SW. Statistical considerations when using a composite endpoint for comparing treatment groups. Stat Med. 2013;32:719-738.
5. Chi GY. Some issues with composite endpoints in clinical trials. Fundam Clin Pharmacol. 2005;19:609-619.
6. Tomlinson, G. Detsky, AS. Composite end points in randomized trials. There is no free lunch. JAMA. 2010;303:267-268.
7. International Conference on Harmonisation E9 Expert Working Group. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Stat Med. 1999;18:105-1942.
8. Kleist, P. Composite endpoints for clinical trials. Int J Pharmaceut Med. 2007;21:187-198.
9. Freemantle N, Calvert M. Weighing the pros and cons for composite outcomes in clinical trials. J Clin Epidemiol. 2007;60:658-659.
10. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, Alonso-Coello P, Alonso J, Worster A, Upadhye S, Jaeschke R, Schünemann HJ, Permanyer-Miralda G, Pacheco-Huergo V, Domingo- Salvany A, Wu P, Mills EJ, Guyatt GH. Problems with use of composite end points in cardiovascular trials: systematic review of randomized controlled trials. Br Med J. 2007;334:786.
11. Ferreira-González I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, Walter SD, Guyatt GH. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol. 2007;60:651-7; discussion 658.
12. Ferreira-González I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, Walter, SD, Guyatt GH. Composite endpoints in clinical trials: the trees and the forest. 2007. J Clin Epidemiol. 2007;60:660-661.
13. Huque MF, Alosh M, Bhore R. Addressing multiplicity issues of a composite endpoint and its components in clinical trials. J Biopharm Stat. 2011;21:610-634.
14. Gómez G, Gómez-Mateu M. The Asymptotic Relative Efficiency and the ratio of sample sizes when testing two different null hypotheses. SORT. 2014 (In Press).
15. Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA; ARISE Trial Investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebocontrolled trial. Lancet. 2008;371(9626):1761-1768.
16. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.
17. Oldgren J, Wallentin L, Afzal R, Bassand JP, Budaj A, Chrolavicius S, Fox KA, Granger CB, Mehta SR, Pais P, Peters RJ, Xavier D, Zhu J, Yusuf S; OASIS-6 Investigators. Effects of fondaparinux in patients with ST- segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J. 2008;29:315-323.
18. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in atients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-2141.
19. Hirsch A, Windhausen F, Tijssen JG, Oude Ophuis AJ, van der Giessen WJ, van der Zee PM, Cornel JH, Verheugt FW, de Winter RJ; Invasive versus Conservative Treatment in Unstable coronary Syndromes Investigators. Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non- ST-segment elevation acute coronary syndrome: the problem of treatment selection bias. Eur Heart J. 2009;30:645-654.
20. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure.N Engl J Med. 2008;358:2667-2677.
21. Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M, Ksiezycka E, Przyluski J, Piotrowski W, Maczynska R, Ruzyllo W. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008;29:1350-1358.
22. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372:1223-30.
23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344-349.
24. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.
25. Editorial: Should protocols for observational research be registered? Lancet 2010; 375:348.